ReviewCurrent topics in medicinal chemistry2014
Structure-based virtual screening for drug discovery: principles, applications and recent advances.
Review in Current topics in medicinal chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 407 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
407 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Expression of multidrug efflux pump gene acrAB in Escherichia coli: a systematic review and meta analysis.BMC infectious diseases · 2025Pooled it
- Bio-active designed peptide for hair keratin strengthening.International journal of cosmetic science · 2026Article
- Computational Evaluation of Carbazole-Chalcone Urea and Thiourea Derivatives Against EGFR: Molecular Docking, Pharmacokinetic Profiling, Target Prediction, and Molecular Dynamics Simulation.Molecules (Basel, Switzerland) · 2026Article
- DockM8: an all-in-one open-source platform for consensus virtual screening in drug design.Journal of cheminformatics · 2026Article
- Virtual Screening and Molecular Dynamics Simulations Identifying Natural Product-Derived Cathepsin K Inhibitors as Potential Therapeutics for Osteoporosis.International journal of molecular sciences · 2026Article
- Molecular Docking of Natural Products: Critical Appraisal of Current Methodology and Practical Guidelines.Molecules (Basel, Switzerland) · 2026Review
- Novel Phosphodiesterase‑2 Inhibitors Discovered via Structure-Based Virtual Screening Targeting the Allosteric GAF‑B Domain.ACS medicinal chemistry letters · 2026Article
- Chemical Characterization and Pharmacological Activity of Byrsonima crassifolia (L.) Kunth (Murici): Antinociceptive Effects, Edema Reduction, and Molecular Docking.Chemistry & biodiversity · 2026Article
- Machine learning-driven identification of PIM2 kinase inhibitors through QSAR modeling and molecular dynamics simulations.Journal, genetic engineering & biotechnology · 2026Article
- Phytochemical Analysis Using LC-MS/MS and Anticancer Activity of Asphodelus tenuifolius Roots: Cell Cycle Arrest, Apoptosis, and In Silico Insights.Chemistry & biodiversity · 2026Article
- Antifungal Activity of Hedychium spicatum Essential Oil Against Candidemia-Causing Candida tropicalis and Candida parapsilosis: In Vitro Evaluation and Computational Identification of Cis-γ-Bisabolene as a Putative CYP51-Binding Constituent.Chemistry & biodiversity · 2026Article
- Integrated AI-Driven Discovery of MAPK3 Inhibitors for Oral Inflammatory and Proliferative Diseases.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Article
- Phytochemical Characterization ofMolecules (Basel, Switzerland) · 2026Article
- Escin ameliorates letrozole-induced polycystic ovarian syndrome by modulating inflammatory, oxidative stress, and steroidogenic pathways in Wistar rats: integration of network pharmacology and molecular docking.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Geometric Deep Learning-Based Drug Design Models for Small-Molecule Drug Discovery.Molecular informatics · 2026Review
- Antioxidant and Antihypertensive Activities of Ficus exasperata Vahl Leaves: Integrated In Vitro Evaluation and In Silico Multi-Target Mechanistic Insights.Chemistry & biodiversity · 2026Article
- From Marine Peptides to Oncology: The Therapeutic Potential of Conotoxins in Cancer Treatment.Chemistry & biodiversity · 2026Review
- Novel Inhibitors of Carbonic Anhydrase I and II Identified by High Throughput Virtual Screening and Validated by X-Ray Crystallography.ChemMedChem · 2026Article
- In silico pipeline for GSK 3β inhibitor discovery in Alzheimer's disease using pharmacophore screening, docking, ADME filtering, and MD validation.Scientific reports · 2026Article
347 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Structure-based drug discovery (SBDD) is becoming an essential tool in assisting fast and cost-efficient lead discovery and optimization. The application of rational, structure-based drug design is proven to be more efficient than the traditional way of drug discovery since it aims to understand the molecular basis of a disease and utilizes the knowledge of the three-dimensional structure of the biological target in the process. In this review, we focus on the principles and applications of Virtual Screening (VS) within the context of SBDD and examine different procedures ranging from the initial stages of the process that include receptor and library pre-processing, to docking, scoring and post-processing of topscoring hits. Recent improvements in structure-based virtual screening (SBVS) efficiency through ensemble docking, induced fit and consensus docking are also discussed. The review highlights advances in the field within the framework of several success studies that have led to nM inhibition directly from VS and provides recent trends in library design as well as discusses limitations of the method. Applications of SBVS in the design of substrates for engineered proteins that enable the discovery of new metabolic and signal transduction pathways and the design of inhibitors of multifunctional proteins are also reviewed. Finally, we contribute two promising VS protocols recently developed by us that aim to increase inhibitor selectivity. In the first protocol, we describe the discovery of micromolar inhibitors through SBVS designed to inhibit the mutant H1047R PI3Kα kinase. Second, we discuss a strategy for the identification of selective binders for the RXRα nuclear receptor. In this protocol, a set of target structures is constructed for ensemble docking based on binding site shape characterization and clustering, aiming to enhance the hit rate of selective inhibitors for the desired protein target through the SBVS process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.